News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,312 Results
Type
Article (8038)
Company Profile (140)
Press Release (476229)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166745)
Career Advice (304)
Deals (25739)
Drug Delivery (7)
Drug Development (52873)
Employer Resources (14)
FDA (9760)
Job Trends (8572)
News (238198)
Policy (17898)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (487)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33162)
ALS (104)
Alzheimer's disease (973)
Antibody-drug conjugate (ADC) (262)
Approvals (10368)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6963)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (506)
Cancer (3627)
Cardiovascular disease (217)
Career advice (246)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47842)
Collaboration (1236)
Commercialization (3)
Compensation (1445)
Complete response letters (34)
COVID-19 (756)
CRISPR (63)
C-suite (735)
Cystic fibrosis (85)
Data (5609)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4175)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73589)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87589)
Executive appointments (698)
FDA (12363)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (908)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (289)
Government (950)
Grass and pollen (2)
Guidances (281)
Healthcare (9323)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (944)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (42)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5209)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (505)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (527)
Marketing (8)
MASH (118)
Medical device (8650)
Medtech (8790)
Mergers & acquisitions (14378)
Metabolic disorders (703)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1816)
NextGen: Class of 2026 (3153)
Non-profit (846)
Obesity (222)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (501)
Peanut (31)
People (41227)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15457)
Phase 2 (21367)
Phase 3 (14388)
Pipeline (7161)
Policy (18)
Postmarket research (1572)
Preclinical (6536)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3021)
Recruiting (6)
Regulatory (14792)
Reports (19)
Research institute (582)
Resumes & cover letters (46)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2018)
Stomach cancer (3)
Supply chain (50)
Vaccines (317)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (93)
Last 7 days (497)
Last 30 days (1643)
Last 365 days (19131)
2026 (11938)
2025 (19251)
2024 (22989)
2023 (26542)
2022 (34587)
2021 (37169)
2020 (33480)
2019 (23278)
2018 (17469)
2017 (18765)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18138)
2012 (20221)
2011 (20440)
2010 (20333)
Location
Africa (228)
Alabama (72)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17876)
Australia (2097)
California (11863)
Canada (3116)
China (515)
Colorado (479)
Connecticut (405)
Delaware (207)
Europe (24610)
Florida (1773)
Georgia (372)
Hawaii (3)
Idaho (46)
Illinois (694)
India (48)
Indiana (314)
Iowa (14)
Japan (397)
Kansas (100)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1188)
Massachusetts (7806)
Michigan (306)
Minnesota (558)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2602)
New Mexico (12)
New York (2799)
North Carolina (1266)
North Dakota (4)
Northern California (5938)
Ohio (275)
Oklahoma (14)
Oregon (16)
Pennsylvania (2241)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4923)
Tennessee (119)
Texas (1915)
United States (38553)
Utah (357)
Vermont (1)
Virginia (152)
Washington D.C. (38)
Washington State (919)
West Virginia (1)
Wisconsin (73)
484,312 Results for "ribometrix inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
Ribometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting
Ribometrix today announced it will present two posters with preclinical data highlighting advancements across two distinct modalities at the 2024 American Association for Cancer Research (AACR) Annual Meeting.
March 11, 2024
·
3 min read
Bio NC
Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024
Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, shared the full data from two posters highlighting advancements across two distinct modalities presented at the 2024 American Association for Cancer Research Annual Meeting, held April 5-10 in San Diego, CA.
April 7, 2024
·
6 min read
Press Releases
Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer
January 10, 2025
·
4 min read
Bio NC
Ribometrix Demonstrates Rapid Progress for eIF4E Program at San Antonio Breast Cancer Symposium
Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today presented preclinical data supporting the potential of its eIF4E inhibitors in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium (SABCS), held December 5-9, 2023, in San Antonio, TX.
December 8, 2023
·
4 min read
Bio NC
Ribometrix to Present Additional Preclinical Data for eIF4E Program at the San Antonio Breast Cancer Symposium
Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today announced it will present preclinical data showing anti-tumor benefit of eIF4E inhibition in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium, held December 5-9, 2023, in San Antonio, TX.
November 29, 2023
·
2 min read
Bio NC
Ribometrix Announces Lead Program Target and Presentation of Preclinical Data at the International Congress of the Society for Melanoma Research
Ribometrix today disclosed its lead wholly-owned development program targeting the protein eIF4E, and announced it will present initial preclinical data demonstrating the anti-tumor benefit of eIF4E inhibition at the 20th International Congress of the Society for Melanoma Research (SMR), held November 6-9, 2023, in Philadelphia, PA.
November 6, 2023
·
4 min read
Press Releases
Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
September 16, 2024
·
4 min read
Business
Ribometrix Promotes Dr. Manjunath Ramarao to Chief Scientific Officer
Ribometrix announced today the promotion of Manjunath (Manju) Ramarao, Ph.D., to chief scientific officer.
March 21, 2022
·
2 min read
Business
Ribometrix Appoints Dr. Manjunath Ramarao as Senior Vice President of Research
Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, announced the appointment of Manjunath Ramarao, Ph.D., as senior vice president in its research and development team.
June 28, 2021
·
2 min read
Business
Ribometrix and Genentech Partner in Potential $1 Billion+ RNA Deal
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech to identify and advance novel RNA-targeted small molecule therapeutics.
January 6, 2021
·
2 min read
·
Mark Terry
1 of 48,432
Next
